IL308045A - טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים - Google Patents

טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים

Info

Publication number
IL308045A
IL308045A IL308045A IL30804523A IL308045A IL 308045 A IL308045 A IL 308045A IL 308045 A IL308045 A IL 308045A IL 30804523 A IL30804523 A IL 30804523A IL 308045 A IL308045 A IL 308045A
Authority
IL
Israel
Prior art keywords
treatment
lupus nephritis
baffr antibodies
baffr
antibodies
Prior art date
Application number
IL308045A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL308045A publication Critical patent/IL308045A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL308045A 2021-05-04 2022-05-03 טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים IL308045A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163184046P 2021-05-04 2021-05-04
PCT/IB2022/054056 WO2022234440A1 (en) 2021-05-04 2022-05-03 Treatment for lupus nephritis using anti-baffr antibodies

Publications (1)

Publication Number Publication Date
IL308045A true IL308045A (he) 2023-12-01

Family

ID=81655080

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308045A IL308045A (he) 2021-05-04 2022-05-03 טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים

Country Status (9)

Country Link
US (1) US20240239911A1 (he)
EP (1) EP4334352A1 (he)
JP (1) JP2024517796A (he)
KR (1) KR20240004760A (he)
CN (1) CN117203240A (he)
CA (1) CA3216063A1 (he)
IL (1) IL308045A (he)
TW (1) TW202302147A (he)
WO (1) WO2022234440A1 (he)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121752276A (zh) * 2023-09-08 2026-03-27 菲特治疗公司 用于自身免疫疾病治疗的iPSC衍生的效应细胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101120021A (zh) * 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
SI2315780T1 (sl) * 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation

Also Published As

Publication number Publication date
JP2024517796A (ja) 2024-04-23
KR20240004760A (ko) 2024-01-11
EP4334352A1 (en) 2024-03-13
CN117203240A (zh) 2023-12-08
TW202302147A (zh) 2023-01-16
US20240239911A1 (en) 2024-07-18
WO2022234440A1 (en) 2022-11-10
CA3216063A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
IL279063A (he) תאי t לקולטן אנטיגן כימרי לטיפול בסרטן
IL281449A (he) נוגדנים אנטי- ifnar1 לטיפול במחלות אוטואימוניות
IL277861A (he) נוגדנים ספציפיים ל axl לטיפול בסרטן
PL3728271T3 (pl) Związki makrocykliczne do leczenia chorób
EP3990022A4 (en) Anti-cd33 antibodies for treating cancer
ZA201907460B (en) Improved protocol for treatment of lupus nephritis
GB201911685D0 (en) Process for purifying monoclonal antibodies
IL289842A (he) נוגדנים אנטי- liv1 אנושיים לטיפול בסרטן
IL276875A (he) נוגדנים אנטי cd6 לטיפול באסתמה חמורה
IL289201A (he) תרכובות לטיפול בסרטן
GB201909468D0 (en) Compounds for treating cancer
SG11202007924TA (en) Method for introducing mutations
IL277056A (he) שיטה לטיהור נוגדנים
IL308045A (he) טיפול במחלת לופוס נפריטיס באמצעות נוגדנים אנטי-באפריים
IL308393A (he) נוגדנים לטיפול במחלות אלפא-סינוקליאיניות
IL289959A (he) שיטות לטיהור נוגדנים
IL284668A (he) שיטות לטיפול בסכיזופרניה
IL290582A (he) שיטה לסינתזה של פניל-5-הידרוקסי מתיל-2- אוקסאזולידינון מותמרים ב-n
IL308044A (he) טיפול בלופוס אריתמטוזוס מערכתי באמצעות נוגדנים אנטי-באפריים
SG11202102683XA (en) Treatment for obesity
GB201909466D0 (en) Compounds for treating cancer
HK40039204A (en) Anti-ifnar1 antibodies for treating autoimmune diseases
HK40109315A (en) Antibodies for treating alpha-synucleinopathies
HK40046198A (en) Axl-specific antibodies for cancer treatment
GB201903547D0 (en) Treatment for autoimmune diseases